Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Torrent Pharmaceuticals Ltd

₹ 4,0150.25%
16 Jan 3:25 p.m. – close price
🔗torrentpharma.com•BSE: 500420•NSE: TORNTPHARM
Market Cap₹ 1,35,888 Cr.
Current Price₹ 4,015
High / Low₹ 4,106
Stock P/E63.6
Book Value₹ 250
Dividend Yield0.81 %
ROCE27.8 %
ROE26.2 %
Face Value₹ 5.00
Sales₹ 10,188 Cr.
OPM37.4 %
Mar Cap₹ 1,35,888 Cr.

ABOUT

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]

KEY POINTS

Product Segments Q2 FY251) Branded Generics (74%):[1]The company’s branded generics business focuses on the manufacturing pharmaceutical products under its brand names catering to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management and gynecology. Its branded generic medicines are marketed in key regions including India and Brazil.[2]

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsPreferential IssuanceOrder Book PositionOrder Book PositionJv Partnerships AcquisitionsJv Partnerships AcquisitionsCredit Rating UpdatesCredit Rating UpdatesRed Flags And Poor PerformanceRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1670.0034.66400689.010.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1212.970.07
2.Divi's Lab.6230.5066.56165400.150.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7013.530.01
3.Torrent Pharma.4015.0563.65135887.520.81597.0031.842762.0013.4827.7510188.0037.362134.28606.4516.0915.010.25
4.Cipla1398.5020.75112966.890.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2178.9023.1299531.800.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1012.410.32
6.Dr Reddy's Labs1175.6517.0398123.310.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2175.8551.4089820.180.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
–Median: 149 Co.399.529.971770.920.1213.4911.71161.7610.5814.89591.7315.9345.2613.963.158.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
1,9281,9151,9202,1212,1462,1232,1432,4382,4342,3772,4332,6162,762
Expenses
1,3081,3121,3421,3841,4101,4221,4271,5391,5131,4901,5651,6371,690
Operating Profit
6206035787377367017168999218878689791,072
Other Income
1115261115-117621-73-9-5-40
Profit before tax
413342328475482430530667670651622742806
Tax %
34%32%33%32%32%31%23%30%31%26%24%26%26%
Net Profit
272234219323327297410469460485474551597
EPS in Rs
8.046.916.479.549.668.7812.1113.8613.5914.3314.0116.2817.64

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
3,3583,4685,4394,5514,2445,7626,1686,4516,7427,6958,5339,68210,188
Expenses
2,2942,6242,9903,4243,3374,1494,2514,2594,6425,2305,6446,1076,382
Operating Profit
1,0658432,4501,1279071,6131,9172,1922,1012,4652,8893,5763,806
Other Income
3230629230033238223711820482917-51
Interest
58173180202294481430334236298303213177
Depreciation
79180213269384579607610602672761759757
Profit before tax
9587962,3489555629351,1171,3661,4661,5771,9172,6102,821
Net Profit
7626231,7438544827459391,1389911,0511,3571,8882,107
EPS in Rs
22.5318.4251.5125.2414.2422.0327.7333.6229.3031.0740.1055.7962.26
Dividend Payout %
22%31%34%28%49%39%58%52%82%71%70%11%–

Compounded Sales Growth

10 Years:11%
5 Years:9%
3 Years:13%
TTM:11%

Compounded Profit Growth

10 Years:12%
5 Years:16%
3 Years:24%
TTM:30%

Stock Price CAGR

10 Years:19%
5 Years:24%
3 Years:36%
1 Year:26%

Return on Equity

10 Years:20%
5 Years:20%
3 Years:21%
Last Year:26%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
858585858585858585169169169169
Reserves
2,2052,6213,6234,3694,4724,9315,0365,9456,2616,2876,6607,4238,286
Borrowings
1,1322,5212,2492,4465,8455,6235,2944,4043,3484,5753,3442,6292,115
Other Liabilities
9111,2701,3321,1521,4191,3891,4691,3271,4601,8402,2042,6202,755
Total Liabilities
4,3336,4977,2898,05111,82012,02711,88411,76111,15312,87212,37712,84213,325
Fixed Assets
8362,7642,6813,5237,4297,4257,1986,7416,2517,9727,9867,5547,319
Gross Block
1,3213,4163,5324,6348,9059,5689,8069,95310,00212,36713,00013,301–
Accumulated Depreciation
4856538501,1111,4772,1432,6083,2123,7514,3955,0145,747–
CWIP
508628984473447498536588568698226402485
Investments
322434918936625486135314368361463523530
Other Assets
2,6672,6722,7053,1193,3193,6184,0164,1183,9663,8413,7014,3634,991
Total Assets
4,3336,4977,2898,05111,82012,02711,88411,76111,15312,87212,37712,84213,325

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
3101,0652,4036769291,2321,5801,5732,1402,2652,8932,574
Cash from Investing Activity
-326-2,099-584-527-4,207-373269-316-160-2,326-296-470
Cash from Financing Activity
86996-1,326-1302,929-928-1,555-1,581-1,97781-2,578-2,104
Net Cash Flow
70-3849319-349-69294-32532019-0

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
14312461829586898783826782
Inventory Days
253263299272425321336418344273268254
Days Payable
175212205144254138152142119104130125
Cash Conversion Cycle
222175155209267269273364308251205211
Working Capital Days
1211095312010527675102243
ROCE %
35%22%44%17%9%13%14%16%17%18%21%28%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
71.25%71.25%71.25%71.25%71.25%71.25%71.25%71.25%68.31%68.31%68.31%68.31%68.31%
FIIs
12.09%12.04%12.85%13.15%14.08%14.14%14.22%14.46%16.17%16.31%16.09%15.92%16.13%
DIIs
8.77%8.89%8.22%7.91%7.11%7.15%7.17%6.98%8.25%8.25%8.54%9.17%9.05%
Public
7.78%7.71%7.59%7.59%7.46%7.34%7.25%7.21%7.17%7.02%6.93%6.47%6.41%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Torrent Pharma Sells Associate Shares for ₹5 Lakh

31st March 2026, 1:40 am

Torrent Pharma Calls Shareholder Meeting for Amalgamation with JB Chemicals

28th March 2026, 10:51 pm

Torrent Pharma Closes Trading Window from April 1 for Audited Results

28th March 2026, 5:55 pm

Torrent Pharma to Hold Shareholder Meeting for JB Chemicals Amalgamation

28th March 2026, 2:00 am

Torrent Pharma provides update on Amalgamation: NCLT issues Corrigendum Order for J.B. Chemicals merger

26th March 2026, 1:41 am

Published by Other Websites

External media mentions & references

US Tariffs Threaten Pharma Stocks, Nifty Index Plunges 4%

2nd April 2026, 1:50 pm

Pharma Tumble, IndiGo Charges Hit Indian Markets

2nd April 2026, 1:11 pm

PE-VC Exits Plummet 40% in FY26 Amid Volatile Markets

1st April 2026, 7:37 pm

VIX Surge Sparks Volatility Fears; Pharma Rallies, Financials Oversold

30th March 2026, 6:17 am

India's Semaglutide Generics Launch Price War, Slashes Costs

23rd March 2026, 3:27 pm

News Articles

Editorial & research coverage

Corporate Action Surge: 50+ Firms Eye Shareholder Payouts Amid Market Wobble
Corporate Action Surge: 50+ Firms Eye Shareholder Payouts Amid Market Wobble

13th February 2026, 1:31 pm

Market Movers: Banks Mixed, Industrials Surge, Pharma Faces Scrutiny
Market Movers: Banks Mixed, Industrials Surge, Pharma Faces Scrutiny

27th January 2026, 7:08 am

Torrent Pharma Takes Control of JB Pharma, Ousts CEO, Appoints New MD
Torrent Pharma Takes Control of JB Pharma, Ousts CEO, Appoints New MD

21st January 2026, 9:14 pm

Torrent Pharma Seals JB Chem Deal, Forges India's #2 Pharma Giant
Torrent Pharma Seals JB Chem Deal, Forges India's #2 Pharma Giant

21st January 2026, 4:00 pm

Nifty Dips Below 25.6k; Wipro Plunges 8% on Weak Outlook
Nifty Dips Below 25.6k; Wipro Plunges 8% on Weak Outlook

20th January 2026, 6:17 am

Documents

Announcements

Announcement under Regulation 30 (LODR)-Credit Rating

5 Jan - ICRA reaffirmed long-term rating [ICRA] AA+ (Stable); commercial paper rated A1+, enhanced amount assigned.

Announcement under Regulation 30 (LODR)-Issue of Securities

5 Jan - Approved issuance of secured, rated, listed NCDs up to ₹12,500 crore via private placement (05 Jan 2026).

Board Meeting Outcome for Issuance Of Secured, Rated, Listed, Redeemable Non-Convertible Debentures ('Ncds')

5 Jan - Approved issuance of secured, rated, listed NCDs up to ₹12,500 crore via private placement, to be listed on NSE WDM.

Announcement under Regulation 30 (LODR)-Credit Rating

2 Jan - India Ratings affirmed IND AA+(Stable) for bank facilities, issuer and NCDs; assigned IND A1+ for proposed CP (02 Jan 2026).

Board Meeting Intimation for To Consider And Approve The Proposal For Issuance Of Secured Non-Convertible Debentures On Private Placement Basis

30 Dec - Committee meeting on 05-Jan-26 to consider issuance of secured NCDs via private placement within Board-approved limits.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Financial Year 2012

(from nse)

Credit Ratings

Rating update

5 Jan from icra

Rating update

2 Jan from fitch

Rating update

6 Oct 2025 from fitch

Rating update

8 Jul 2025 from icra

Rating update

19 Mar 2025 from icra

Rating update

23 Aug 2024 from icra

Concalls

Nov 2025

TranscriptPPTRecording

Jul 2025

TranscriptPPT

May 2025

Transcript

Jan 2025

Transcript

Oct 2024

TranscriptRecording

Jul 2024

Transcript

May 2024

Transcript

Feb 2024

Transcript

Aug 2023

Transcript

May 2023

Transcript

Sep 2022

PPT

May 2021

Transcript

Feb 2021

Transcript

Oct 2020

Transcript

Jul 2020

Transcript

May 2020

Transcript

Oct 2019

Transcript

Jul 2019

Transcript

May 2019

Transcript

Jan 2019

Transcript

Oct 2018

Transcript

Jul 2018

Transcript

May 2018

PPT

May 2018

TranscriptPPT

Feb 2018

TranscriptPPT

Feb 2018

PPT

Oct 2017

Transcript

May 2017

Transcript

Jan 2017

Transcript

Oct 2016

Transcript

May 2016

Transcript

Stock Analysis

Description

  1. Torrent Pharmaceuticals Ltd. is a leading Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. It is the flagship company of the Torrent Group, which also has interests in power and city gas distribution.

Key Growth Triggers

  1. Robust Q2 FY26 performance with strong revenue and profit growth across key geographies like India, the US, and Brazil.
  2. Progress in acquiring a controlling stake in J.B. Chemicals & Pharmaceuticals, with key regulatory approvals secured.
  3. Clean USFDA inspection for its Vizag manufacturing facility, reinforcing compliance and quality.
  4. Strategic investments in renewable energy through its group company, Torrent Urja.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Received penalty orders from NPPA and CGST authorities for alleged overcharging and refund claims, although the company has assessed no material financial impact.
  2. Stock is trading at a relatively high Price to Book (PB) ratio of 15.6x based on historical data.

Key Dates To Watch

  1. November 7, 2025: Board Meeting to consider and approve the company's financial results for the quarter and half-year ended September 30, 2025.
  2. November 7, 2025: Post-quarterly financial results conference call for investors and analysts.

Corporate Announcements

30th Mar 26
Impact Rating: 6
Torrent Pharmaceuticals announced the sale of 50,000 equity shares of UNM Foundation, a Section 8 company, for ₹5.00 lakh (₹0.05 cr) to its holding company, Torrent Investments Limited.
28th Mar 26
Impact Rating: -
No description available.
28th Mar 26
Impact Rating: 6
Torrent Pharma will shut its trading window for company insiders from April 1, 2026. This is standard procedure before announcing the audited financial results for the fiscal year ending March 31, 2026. The window will reopen 48 hours after results submission.
27th Mar 26
Impact Rating: 8
Torrent Pharmaceuticals has scheduled a crucial shareholder meeting for April 28, 2026, to seek approval for its amalgamation with J.B. Chemicals & Pharmaceuticals.
25th Mar 26
Impact Rating: 8
Torrent Pharmaceuticals updated exchanges on the proposed amalgamation with J.B. Chemicals. The NCLT Ahmedabad Bench issued a corrigendum order on March 24, 2026, related to the scheme.